Upfront payment of 0.8 hundred million USD, milestone payments of 0.2 hundred million USD, sales royalty of 20%, with clinical trials, regulatory approvals and sales to be handled in Japan, Korea, Taiwan and ASEAN. The lead asset BHV-1300 is targeting Graves’ disease and is in global Phase 3 trials. Impact on consolidated results for the fiscal year ending March 2027 is minimal.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4528","jir_company_name":"Ono Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4528-20261008-01.pdf","jir_short_summary":"Upfront payment of 0.8 hundred million USD, milestone payments of 0.2 hundred million USD, sales royalty of 20%, with clinical trials, regulatory approvals and sales to be handled in Japan, Korea, Taiwan and ASEAN. The lead asset BHV-1300 is targeting Graves' disease and is in global Phase 3 trials. Impact on consolidated results for the fiscal year ending March 2027 is minimal.","jir_summary":"### Agreement Overview\nOno Pharmaceutical Co., Ltd. has entered into an exclusive license agreement with Biohaven for IgG-degrading drug assets (BHV-1300, BHV-1310, BHV-1320) for development and commercialization in Japan, Korea, Taiwan and ASEAN countries. Under the agreement, Ono Pharmaceutical will pay an upfront payment of 0.8 hundred million USD, milestone payments of 0.2 hundred million USD based on progress, and approximately 20% of sales as royalties to Biohaven. Ono Pharmaceutical will be responsible for conducting clinical trials, obtaining regulatory approvals, and commercial sales. The most advanced asset, BHV-1300, is currently in global Phase 3 trials targeting Graves' disease.\n\n### Future Impact and Outlook\nThis collaboration strengthens the medium- to long-term strategy in the immunology and inflammation field, creating opportunities to provide new treatment options for patients with Graves' disease and to expand the market. The impact on consolidated results for the fiscal year ending March 2027 is expected to be minimal; further disclosures will be made as required. By combining Biohaven's technological capabilities with Ono Pharmaceutical's Asian market development strength, the parties aim to accelerate clinical development and commercialization.","jir_financial_highlights":"Upfront payment: 0.8 hundred million USD (Unknown)\nMilestones: 0.2 hundred million USD (Paid according to progress)\nRoyalty: approx. 20% (Unknown)","jir_category":"","jir_hashtags":"#OnoPharmaceuticalCoLtd, #NewPartnership, #IgGDegradingTherapy, #MoDEPlatform","jir_key_figures":"Upfront payment: 0.8 hundred million USD\nMilestones: 0.2 hundred million USD\nRoyalty: approx. 20%","jir_meta_title":"Ono Pharmaceutical Co., Ltd. Concludes Exclusive License Agreement with Biohaven for IgG-Degrading Drug Assets\uff5cOctober 2026","jir_meta_description":"Ono Pharmaceutical Co., Ltd. has executed an exclusive development and commercialization license agreement with Biohaven for IgG-degrading drug assets. Upfront payment of 0.8 hundred million USD, milestone payments of 0.2 hundred million USD, and a 20% royalty will be paid. Ono Pharmaceutical will handle clinical trials, approvals and sales in Japan, Korea, Taiwan and ASEAN. The lead asset is in global Phase 3 for Graves' disease.","jir_og_title":"Ono Pharmaceutical Co., Ltd. Enters Exclusive License Agreement for IgG-Degrading Drug Assets\uff5cOctober 2026","jir_og_description":"Ono Pharmaceutical Co., Ltd. announced an exclusive license agreement with Biohaven for IgG-degrading drug assets. Upfront 0.8 hundred million USD, milestones 0.2 hundred million USD, sales royalty 20%, with development and sales in Japan, Korea, Taiwan and ASEAN handled by Ono Pharmaceutical.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7530,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-128648","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n